Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Revolution Medicines, a clinical-stage oncology company (Nasdaq: RVMD), announced that CEO Mark A. Goldsmith will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. Eastern Time. The conference runs from September 13-15, 2021, in a virtual format with a live webcast accessible on the company’s website. Revolution Medicines specializes in developing targeted therapies for RAS-addicted cancers, with its R&D pipeline including RAS(ON) Inhibitors and RAS Companion Inhibitors.

REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 23^rd Annual Global Investment Conference.

Details of the company’s participation are as follows:

• H.C. Wainwright 23^rd Annual Global Investment Conference
  Conference Dates: September 13-15, 2021
  Presentation Timing: 7:00 a.m. Eastern on Monday, September 13, 2021
  Format: Virtual conference; webcast available

To access the live webcast of the presentation, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

FAQ

When will Revolution Medicines present at the H.C. Wainwright conference?

Revolution Medicines will present on September 13, 2021, at 7:00 a.m. Eastern Time.

What is the focus of Revolution Medicines' research and development?

Revolution Medicines focuses on developing targeted therapies for RAS-addicted cancers.

Where can I watch the Revolution Medicines conference presentation?

The presentation can be watched live on the company's 'Events & Presentations' page on its website.

What are RAS(ON) Inhibitors?

RAS(ON) Inhibitors are targeted therapies aimed at suppressing various oncogenic variants of RAS proteins.

What dates will the H.C. Wainwright conference occur?

The H.C. Wainwright conference will take place from September 13-15, 2021.